Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Tuesday 21 October 2014 1:46 pm  |  Updated:  Friday 07 June 2019 2:08 pm

Is there a cure for Ebola? Antibody serum from survivors’ blood could be used in Liberia within weeks

By: Sarah Spickernell

Add as a preferred source on Google

A serum containing antibodies produced by Ebola survivors could be used to treat patients in Liberia within weeks, according to the World Health Organisation (WHO). 
 
The deadly virus has killed over 4,500 people in west Africa since the epidemic began in December last year, and Liberia has been one of the worst-affected countries, along with Guinea and Sierra Leone. 
 
Once a person has recovered from Ebola, it means their body has an immune “memory” and can easily kill the virus if it encounters it at a later date. This is because they have antibodies in their blood which are adapted specifically to deal with the virus. 
 
By taking a survivor's blood and removing red blood cells so that only the important antibodies remain, doctors are able to develop a treatment that can be used on current sufferers of the disease. 
 
The results have been promising so far, with Spanish nurse Teresa Romero making a full recovery after being given a sample of the serum. She became the first person to contract Ebola outside of west Africa when she treated two infected Spanish missionaries at a hospital in Madrid.
 
It is currently unknown how much of the serum will be made available and to what extent it will meet the country's needs, but it is hoped that it will provide a significant blow to the outbreak which has shown no sign of abating.
 
There are some risks associated with the serum's use, however. According to Dr Kieny, WHO assistant director general for health system and innovation, all donors will have to be screened for other infectious diseases such as HIV and hepatitis. WHO has also released strict guidelines on how to use it safely.
 
But Kieny remains positive about the serum's potential, and at a conference in Geneva earlier today she said: "There are partnerships which are starting to be put in place to have capacity in the three countries to safely extract plasma and make preparation that can be used for the treatment of infective patients.
 
"The partnership which is moving the quickest will be in Liberia where we hope that in the coming weeks there will be facilities set up to collect the blood, treat the blood and be able to process it for use.”

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Ebola

Trending Articles

  • Burnham tax plans spark investor rush to bank capital gains

  • Nothing fails to file accounts months after dissolution threat

  • Cruyff turn: Starmer allows pubs to stay open for England World Cup game

  • I’ve taken the best train trips in the world. Here are my 5 favourites

  • PwC joins the Canary Wharf crowd in major property shake-up

More from City PM

  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument

    Business Wire
  • Tech, trackers and tourniquets: How England are preparing for Mexico World Cup altitude

    Sport Business
    Getty Images logo on a digital screen, representing a news or business article with visual emphasis on media and photography.
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

    Business Wire
  • IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

    Business Wire
  • Inaction on abusive legal actions is a SLAPP in the face

    Opinion
    The Royal Courts of Justice building with its gothic architecture and iconic facade in London on a bright day
  • Wise triggers staff backlash after cutting paid paternity leave

    Fintech
    Wise said it expected to report a double-digit jump in income ahead of its capital markets day

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy